tumor cell-VEGF induction may promote angiogenesis in adenocarcinoma of the lung; tumor cell expression may be important prognostic factor in adenocarcinoma of the lung

Increased VEGF level is an important parameter in lung cancers.

Surrounding stromal cells activity correlates strongly and positively with VEGF mRNA expression in lung cancer.

angiogenesis develops early in lung carcinogenesis and is associated with overexpression of VEGF

HIF-1alpha and CA IX, but not VEGF or MMP-9, may have a role in progression of surgically resected non-small cell lung cancer

Increased VEGF levels in blood is associated with non-small cell lung cancer

Ganoderma lucidum Polysaccharide Peptide induces VEGF in lung cancer cells.

vascular endothelial growth factor and its receptors are inhibited in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine

Increased serum levels of VEGF is associated with advanced stage non-small cell lung cancer

Serum VEGF level did not increase with stage progression of non-small cell lung cancer, and only had a trend toward elevation in distant metastasis

endothelial and lung cancer cells seem to interact via various paracrine pathways, e.g. by the reciprocal induction of VEGF and PDGF-BB

study found polymorphisms of -460C/T, +405C/G, & +936C/T in the VEGF gene do not play a major role in non-small cell lung cancer risk

oxidative stress and VEGF are significantly increased in patients with primary lung cancer

polymorphisms in VEGF may be associated with survival in early-stage non-small-cell lung cancer

Low serum VEGF concentration is a significant and independent prognostic factor in small cell lung cancer patients

No significant differences in tested SNPs between patients with PD and lung cancer. One haplotype was significantly different in comparisons between the two diseases. VEGF SNPs might help understand the low incidence of lung cancer in patients with PD.

EGFR gene mutations are frequently seen in lung adenocarcinomas with bronchioloalveolar differentiation and can be linked to chromosomal imbalances and increased VEGF expression

Highest levels of circulating VEGF are observed in metastatic stage, positive mediastinal nodal status, and poor PS non-small cell lung cancers.

Case Report: pulmonary tumor thrombotic microangiopathy caused by an ovarian cancer expressing tissue factor and vascular endothelial growth factor.

PRL-3 induces microvascular and lymphatic vessel formation by facilitating VEGF and VEGF-C expression in lung cancer

high levels of pleural effusion VEGF is a negative predictor of non-small cell lung cancer patient survival

VEGF was a highly significant predictor of response to therapy and survival in both limited disease and extensive disease small cell lung cancer patients. Normal serum VEGF level was associated with improved response rate.

The subcellular expression of maspin in pulmonary adenocarcinomas and correlated with histological grade, proliferative rate, p53 expression, vascular endothelial growth factor-A levels, and prognosis

gene poolymorphism and level of expression is associated with lung cancer

expressionin cancer tissue has no prognostic impact in non-small cell lung cancer patients

PCNA and VEGF expression in non-small cell lung cancer regulates angiogenesis and proliferation at the same time.

Data suggest that beta-glucan enhances bevacizumab-mediated efficacy and may provide therapeutic benefits for lung cancers with membrane-bound VEGF expression.

polymorphisms in VEGF may affect survival in advanced non-small-cell lung cancer

The expression levels of both Elf-1 and VEGF were significantly related with tumor differentiation, lymphatic metastasis, clinical stage, and postoperative survival time in non-small cell lung cancer.

The micrometastasis in peripheral blood of non-small cell lung cancer patients is significantly associated with serum VEGF levels.

Suggest that a HIF-1 alpha/VEGF angiogenic pathway may exist in vivo in small cell lung carcinoma.

examines the role of SNPs in the VEGF gene as predictive and prognostic markers for major solid tumors, including the breast, non-small cell lung, colorectal, and prostate cancers

the alternative splicing variant VEGF189, the cell binding isoform, plays a leading role in the progression of non-small cell lung cancer

HIF-1alpha expression is positively correlated with VEGF expression in non-small cell lung cancer.

Serum and bronchoalveolar lavage fluid IL-8 and serum VEGF might have a prognostic role in survival of lung cancer.

the VEGF-stromal cell-derived factor-1alpha/CXCL12 axis may have a role in pleural effusion of lung cancer

Ginsenosides Rg3 can down-regulate the expressions of KDR and VEGF in human lung squamous cancer SK-MES-1 cells.

Investigated maspin, p53 and VEGF expression in patients with squamous cell carcinoma (SCC), adenocarcinoma (AC) and small cell lung carcinoma (SCLC).

vascular endothelial growth factor-A is a prognostic factor for non-small cell lung cancer

Data suggest that determination of HMGB1, survivin and VEGF concentrations has no clinical significance in the prognosis of the survival time in lung cancer.

Data suggest that EGR-1 plays important roles on VEGF-A expression in lung cancer cells, and epigenetic silencing of transactivator(s) associated with NAB-2 expression might also contribute to upregulate VEGF-A expression.

analysis of the role of IL-6 and VEGF in small cell lung cancer

Serum VEGF in patients of non-small cell lung cancer after surgery were elevated. In the group of higher platelet counts, serum VEGF increased more significantly.

VEGF -460 C polymorphisms is associated with better response to chemoradiotherapy in non-small cell lung cancer

The high expression of CAIX in non-small cell lung cancer tissues is correlated with VEGF level but not with Ki67 level.

VEGF-A and VEGF mRNA levels may correlate with FDG uptake and aggressiveness in lung adenocarcinoma

A positive expression of FLNA and VEGF was detected in the cytoplasm of tumor cells in 66 (48.2%) and 69 (50.4%) of the 137 patients with lung cancer, respectively (p<0.0001).

VEGF and IL-18 ratios are different in induced sputum of patients with different types of lung cancer (NSCLC and SCLC), indicating differences in angiogenesis mechanisms and/or immunological response in these two major histological types of lung cancer

can be used as an independent prognostic biomarker in combination with sVEGFR-2 in advanced non-small-cell lung cancer

Cell proteins associated with M1 and M2 macrophages are also expressed by other cell types in the tumour islets and stroma of patients with non-small cell lung cancer

High VEGF is associated with non-small cell lung cancer and is not associated with treatment with COX-2 or 5-LOX inhibitors.

Protein expression of VEGF, EGFR and MMP-9 is elevated in non-small cell lung carcinomas, correlating with progression.

High VEGF is associated with lung adenocarcinoma with malignant pleural effusion.

Low pretreatment plasma levels of VEGF appear to be predictive of a positive effect of celecoxib on survival in advanced non-small cell lung cancer

High mRNA expression of VEGFA is associated with non-small-cell lung cancer.

vascular endothelial growth factor single nucleotide polymorphisms are associated with non-small cell lung cancer tumor angiogenesis through Dll4.

lung cancer Adenocarcinoma and squamous cell carcinoma cell lines exhibit different VEGF-A responses to hypoxia

In this comprehensive evaluation, pretreatment total circulating VEGF-A was prognostic for outcome in metastatic colorectal, lung, and renal cell cancers, but it was not predictive for bevacizumab-based treatment benefit.

Authors present the role of vascular-endothelial growth factor in the process of angiogenesis and the biology of the lung cancer and antiangiogenic therapy directions.[review]

Our study showed that the TT genotype of Vascular endothelial growth factor was associated with increased lung cancer risk than those with the CC genotype

High VEGF expression is associated with low response to chemotherapy in non-small cell lung cancer.

High levels of circulating VEGF predicts poor overall survival in lung cancer, yet it does not predict poor progression free survival. [Meta-analysis]

The level of VEGF showed significant correlations with lymph node metastasis and distant metastasis in in malignant pleural effusions of lung cancer patients.

Autocrine IL-8 and VEGF synergistically activate ATF-2 mediated invasiveness in A549 lung cancer cells.

High vascular endothelial growth factor in bronchoalveolar lavage fluid is associated with primary lung cancer.

Increase of serum VEGF is associated with response to therapy in non- small cell lung cancer.

role of VEGF polymorphism in lung cancer

A allele of VEGF -2578C/A polymorphism might be a risk factor for lung cancer, especially in smoker patients and SCC patients. However, the T allele of VEGF -460C/T polymorphism might be a protective factor for nonsmoker and SCC lung cancer patients.

High serum VEGF levels are associated with advanced stages of non-small cell lung cancer.

common vascular endothelial growth factor polymorphisms (-2578C>A, -460C>T, +936C>T, and +405G>C) in susceptibility to lung cancer

High VEGFA gene expression is associated with early-stage non-small cell lung cancer.

the variant genotypes of the VEGF -2578C/A polymorphism, but not the VEGF -634G/C polymorphism, was associated with lung cancer risk.

survivin and VEGF are over-expressed in small-cell lung cancer and may have a role in tumorigenesis

the detection of CD163+ macrophages and pro-angiogenic factors IL-8 and VEGF reflects the local environmental status of host immunity and can be helpful for diagnosis of cancerous inflammation in the lungs

TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling.

The expression of VEGF is increased in lung cancer cells following nicotine-induced cell proliferation.

Il-6, IL-17, TNF-alpha and VEGF levels were measured in exhaled breath condensate and serum of 15 patients with stage I-IIA non-small cell lung cancer.

The ratio of VEGF/endostatin levels was significantly higher in operable non-small cell lung cancer patients than in normal controls.

RBP2 promotes HIF-1alpha-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.

High VEGF expression is associated with malignant pleural effusions in lung cancer.

VEGF, TGF-beta1, and endostatin significantly contribute to the poor cell differentiation in non-small cell lung cancer

Transcriptomic data in patients with non-small cell lung cancer indicate that TP53 mutations are associated with higher VEGF-A expression.

Gene phenotypic analysis demonstrated that C allele of +405G/C in VEGF gene was significantly associated increased risk of lung cancer in males.

serum VEGF levels were significantly associated with tumor metastasis in small cell lung cancer.

The prepared aptasensor exhibited high sensitivity and good selectivity and reproducibility. The aptasensor was successfully applied to the determination of VEGF165 in serum sample of a lung cancer patient

Data show that serum interleukin 17 (IL-17) was elevated and the levels positively correlated with vascular endothelial growth factor (VEGF) concentration in non-small-cell lung cancer (NSCLC) patients.

miR-497 has a prominent role in suppression of VEGF-A-mediated non-small cell lung cancer cancer cell growth and invasion.

our data suggested that VEGFA contributes to lung cancer progression by inducing a network of angiogenic factors, which might offer potential for therapeutic intervention

VEGF and MMP-9 are overexpressed in lung adenocarcinoma tissues, and they have a synergistic effect on the invasion and metastasis of adenocarcinoma.

Suggest that miR-195, a tumor suppressor miRNA, contributes to the lung metastasis of HCC by negatively regulating FGF2 and VEGFA expression.

HIF-1alpha and VEGF expression was significantly related to liver tumor stage and lymph nodes and lung metastases (P < 0.05). HIF-1alpha expression correlated with VEGF expression in PLC (r = 0.665, P < 0.05).

CHIP may serve as a promising prognostic biomarker for non-small cell lung cancer (NSCLC] patients and it may be involved in NSCLC angiogenesis through regulating VEGF secretion and expression of VEGFR2.

Using a combination of cytokine expression profiling and miRNAs algorithms, we identified VEGFA/CCL2 and FOXO3a as direct targets of miR-1, miR-206 and miR-31, respectively. Importantly, systemic delivery of anti-VEGFA/CCL2 or pre-miR-1, pre-miR-206 and anti-miR-31 significantly inhibited tumor angiogenesis, TAMs accumulation, tumor growth and lung metastasis.

TIPE2 suppressed tumor invasiveness and angiogenesis in non-small cell lung cancer via inhibiting the activation of Rac1 and subsequently weakening its downstream effects, including F-actin polymerization and VEGF expression.

Sulfated fucoidan FP08S2 from Sargassum fusiforme blocks VEGFR2/Erk/VEGF signaling to prevent angiogenesis in lung cancer.

The rs833061T>C of vascular endothelial growth factor A may be a useful prognostic marker for patients with surgically resected non-small cell lung cancer, which has dissimilar roles in different tumor histology.

lung cancer patients showed significantly lower levels of serum VEGF (1.9 fold) and IL-8 (~9 fold) than COPD patients. VEGF level was significantly higher (2.6 fold) in metastatic than non-metastatic cancer patients. An increase in MMP-9 (~1.6 fold) levels was observed in lung cancer patients.

High expression of VEGFA is associated with squamous cell lung carcinoma.

High expression of VEGFA is associated with lung cancer.

The SNPs examined appear to influence lung cancer susceptibility while as genotypes of the SNPs don't appear to have significant association with VEGF mRNA expression in lung tumours.

the erlotinib plus bevacizumab combination demonstrated promising efficacy in the B901L xenograft model of EGFR Mut+ non-small cell lung cancer (NSCLC). Re-induction of VEGF and subsequent direct or indirect VEGF-dependent tumor growth was suggested as a major mechanism of erlotinib resistance, and erlotinib plus bevacizumab achieved remarkably prolonged antitumor activity in this model.

Our results indicate that HPV16 E6/E7 indirectly upregulated the expression of VEGF by inhibition of liver kinase B1 expression and upregulation of hypoxia-inducible factor 2alpha expression,thus propose a human papillomavirus-liver kinase B1-hypoxia-inducible factor 2A-vascular endothelial growth factor axis for the tumorigenesis of lung cancer

these data suggest that PlGF may increase non-small cell lung cancer metastasis through SRp40-mediated mRNA splicing of VEGF.

the presence of elevated circulating levels of VEGF and CXCL1 are predictive of liver and lung metastasis, respectively of colorectal cancer.

Quantity of VEGF mRNA can be used as a prognosis factor to predict shorter overall survival in patients with non-small cell lung carcinoma.

RTPCR analysis revealed that the expression levels of COX2 and VEGF were downregulated following morusin treatment... morusin significantly inhibited the proliferation of the lung cancer cell line A549, and may have affected the invasion and migration of the cells by downregulating the expression of tumor angiogenesisrelated genes.

Adenocarcinomas showed significantly higher staining scores of both VEGF and alphaSMA than squamous cell carcinomas did. In 42 cases of high CD31 score, five-year survival rate (87%) of patients with lung cancer showing mature tumor vessels was significantly better than that (69%) of patients with immature tumor vessels

VEGFA variant +460 T/C may be associated with increased lung cancer risk in Asian populations.

these data highlight an unexpected role of the VEGF165b splice variant in the progression of lung tumors and their response to anti-angiogenic therapies.

In this study, the authors identify VEGF165, a splice variant of VEGF-A, as a regulator of sVEGFR1-i13 expression in lung carcinoma, and further show that VEGF165 cooperates with the transcription factor SOX2 and the splicing factor SRSF2 to control sVEGFR1-i13 expression.

miR1955p acted as a tumor suppressor in squamous cell lung cancer (SQCLC) cells. The expression levels of miR195 were decreased in two SQCLC cell lines (H520 and SKMes1) compared with a normal lung cell line, and miR195 directly targeted the 3'untranslated region of vascular endothelial growth factor (VEGF) in SQCLC cells.

Influence of miR-199a on rats with non-small cell lung cancer via regulating the HIF-1alpha/VEGF signaling pathway.

Circ0021205 aggravates the progression of non-small cell lung cancer by targeting miRNA-16-5p/VEGFA.

a marked association between VEGF -2578C > A A allele / CC genotype and lung cancer risk in overall and Asian populations, but not in in Caucasians (Meta-Analysis)

Syntenin overexpression in human lung cancer tissue and serum is associated with poor prognosis.

LINC00667 promotes the proliferation, migration, and pathological angiogenesis in non-small cell lung cancer through stabilizing VEGFA by EIF4A3.

Effect of malignant-associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer.

LncRNA SNHG16 drives proliferation, migration, and invasion of lung cancer cell through modulation of miR-520/VEGF axis.

Irradiation might increase MMP2, MMP9, and VEGF expression in the tumor tissue of mice bearing Lewis lung cancer.

Ginkgo biloba exocarp extract inhibits tumor angiogenesis, which may be closely relevant to its effect in blockage of Wnt /beta-catenin-VEGF signaling pathway in Lewis lung carcinoma.